Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.77 |
| ▸ | KDR | P35968 | 5/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.55 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073787 | 0.87 | CSF1R (1.00) | CSF1RKDRFLT3AURKBPOLB | |
| SCHEMBL282549 | 0.81 | CSF1R (0.72) | CSF1RKDRFLT3POLBTAAR1 | |
| SCHEMBL22548172 | 0.80 | CSF1R (0.83) | CSF1RAURKB | |
| SCHEMBL282511 | 0.79 | CSF1R (0.60) | CSF1RKDRFLT3 | |
| SCHEMBL282308 | 0.79 | CSF1R (0.70) | CSF1RKDRFLT3POLBTAAR1 | |
| SCHEMBL281954 | 0.79 | CSF1R (0.70) | CSF1RKDRFLT3PDGFRA | |
| SCHEMBL15463609 | 0.79 | KDR (0.64) | CSF1RKDRFLT3AURKBPDGFRA | |
| SCHEMBL5202980 | 0.77 | KDR (0.85) | CSF1RKDRPDGFRA | |
| SCHEMBL22548194 | 0.76 | CSF1R (0.82) | CSF1RKDRAURKB | |
| SCHEMBL22548570 | 0.76 | CSF1R (0.80) | CSF1RKDRFLT3AURKBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | claimed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | claimed |
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | CSF1R 2180/4885KDR 3633/4885FLT3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.